Poll: Preferred treatment plans for mild-stage POAG

Weigh in on our poll!

If diagnosed with mild-stage POAG, what would be your preferred treatment plan?

A. Initiate medical therapy with a topical glaucoma medication.
B. Have selective laser trabeculoplasty (SLT)
C. Have a minimally invasive glaucoma surgery (MIGS)
Related Videos
Xiongfei Liu, MD
Inder Paul Singh, MD
Patrick Mooney, CEO of SpyGlass Pharma
Related Content

ASCRS 2023: Comparing outcomes of 2 different trabecular MIGS devices with or without ab interno canaloplasty for patients with glaucoma

May 12th 2023

Podcast: Celebrate World Glaucoma Week March 7-13, 2021

February 27th 2021

Glaukos announces FDA acceptance of NDA submission for iDose TR

May 8th 2023

ASCRS 2023: Risk factors for glaucoma after infantile cataract surgery

May 7th 2023

ASCRS 2023: Preservative-free vs benzalkonium chloride–preserved latanoprost ophthalmic solution: No relevant efficacy differences for treating POAG and OHT

May 6th 2023

ASCRS 2023: Companies presenting clinical data and technology at annual meeting

May 4th 2023

ASCRS 2023: Comparing outcomes of 2 different trabecular MIGS devices with or without ab interno canaloplasty for patients with glaucoma

May 12th 2023

Podcast: Celebrate World Glaucoma Week March 7-13, 2021

February 27th 2021

Glaukos announces FDA acceptance of NDA submission for iDose TR

May 8th 2023

ASCRS 2023: Risk factors for glaucoma after infantile cataract surgery

May 7th 2023

ASCRS 2023: Preservative-free vs benzalkonium chloride–preserved latanoprost ophthalmic solution: No relevant efficacy differences for treating POAG and OHT

May 6th 2023

ASCRS 2023: Companies presenting clinical data and technology at annual meeting

May 4th 2023

ASCRS 2023: Comparing outcomes of 2 different trabecular MIGS devices with or without ab interno canaloplasty for patients with glaucoma

May 12th 2023

Podcast: Celebrate World Glaucoma Week March 7-13, 2021

February 27th 2021

Glaukos announces FDA acceptance of NDA submission for iDose TR

May 8th 2023

ASCRS 2023: Risk factors for glaucoma after infantile cataract surgery

May 7th 2023

ASCRS 2023: Preservative-free vs benzalkonium chloride–preserved latanoprost ophthalmic solution: No relevant efficacy differences for treating POAG and OHT

May 6th 2023

ASCRS 2023: Companies presenting clinical data and technology at annual meeting

May 4th 2023
© 2023 MJH Life Sciences

All rights reserved.